FINWIRES · TerminalLIVE
FINWIRES

CSPC Pharma, AstraZeneca Enter Development Deal for Potential Renal Disease Drug Candidates

By

CSPC Pharmaceutical (HKG:1093) agreed to a strategic research deal for two of its drug platforms for renal disease treatment with pharmaceutical giant AstraZeneca, according to a Thursday filing.

The collaboration, option and license agreement will cover the Hong Kong-listed drugmaker's siRNA drug discovery and extrahepatic targeted delivery platforms for the development of novel small nucleic acid drug candidates.

CSPC will receive $30 million upfront, up to $540 million in development milestone payments, up to $1.2 billion in sales milestone payments and single-digit royalties based on annual sales.

The two companies plan to use the platforms to develop preclinical candidates. Each resulting program gives AstraZeneca the option to obtain exclusive rights globally or outside China, while CSPC will retain the development, manufacturing and commercialization rights for one of the candidates in China.

Related Articles

Asia

SSY Gets China Production Nod for Methocarbamol Tablets, Registers Phloroglucinol Dihydrate

SSY Group (HKG:2005) obtained production and registration approval for Methocarbamol Tablets and registration approval for Phloroglucinol Dihydrate from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approval for Methocarbamol Tablets came as the drug passed the regulator's consistency evaluation.Methocarbamol Tablets are muscle relaxants mainly used to treat joint and muscle sprains, lumbar muscle strain, and sciatica.Phloroglucinol Dihydrate is used to treat acute spasmodic pain associated with digestive, biliary, urinary, and gynecological conditions.Shares of the firm were up nearly 5% in late morning trade on Thursday.

HKG:2005
Asia

Bellavista Resources Starts Drilling at Canada, Western Australia Projects; Shares Gain 3%

Bellavista Resources (ASX:BVR) started drilling the Pickle Crow gold project in Canada and at its Brumby project in Western Australia, according to a Thursday filing with the Australian bourse.Initial drilling at Pickle Crow for the remainder of the year will assess the open-pit potential on the existing mineral resource of 2.7 million ounces at 7.2 grams per tonne grade of gold, before moving to additional near-surface regional targets in early 2027.At Brumby, the company will assess mineralization continuity for a potential future resource definition drilling program, alongside column leach test work.Bellavista Resources shares gained 3% in recent Thursday trade.

ASX:BVR
Asia

Binastra Unit Bags MYR491 Million Data Center Development Deal

Binastra (KLSE: BNASTRA) unit Binastra Builders secured a 491.2 million ringgit turnkey contract to develop a seven-story data center in Kuala Lumpur, according to a Wednesday Bursa Malaysia filing.The contract, awarded by Exsim Sri Permai, covers the design, construction, testing, commissioning, maintenance and guarantee works, including foundation, substructure, main building and infrastructure works.The project, which also includes a guardhouse, refuse room and electrical substation, is scheduled to begin on July 1 and be completed within 18 months.

KLSE:BNASTRA